Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis (APLS) Thrives on Empaveli, Stiff Competition a Woe
05:19pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Apellis' (APLS) marketed drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.
Apellis (APLS) Thrives on Empaveli, Stiff Competition a Woe
03:03pm, Friday, 22'nd Apr 2022
Apellis' (APLS) marketed drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise.
Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
11:00am, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
WALTHAM, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced results from a global su
Expert Ratings for Apellis Pharmaceuticals
08:31pm, Thursday, 14'th Apr 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with underst
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
02:03pm, Thursday, 14'th Apr 2022 Benzinga
Upgrades
For United Parcel Service Inc (NYSE:UPS), Loop Capital upgraded the previous rating of Hold to Buy. For the fourth quarter, United Parcel Service had an EPS of $3.59, compared to year-ago qua
Why Is Apellis Pharmaceuticals, Inc. (APLS) Up 8.9% Since Last Earnings Report?
03:30pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Apellis Pharmaceuticals, Inc. (APLS) Up 8.9% Since Last Earnings Report?
12:47pm, Wednesday, 30'th Mar 2022
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?
Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development
05:03pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
08:01pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its prev
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto
Novartis AG (NYSE: NVS) said the U.S.
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
11:00am, Thursday, 24'th Mar 2022 GlobeNewswire Inc.
WALTHAM, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its unde
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
08:03pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
WALTHAM, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced a
Why Apellis Pharmaceuticals Stock Is Falling After Hours
04:33pm, Wednesday, 23'rd Mar 2022
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million of its common stock. All o
Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing
04:00pm, Wednesday, 16'th Mar 2022 Investor''s Business Daily
Apellis said Wednesday it plans to ask the FDA to approve its eye-disease treatment in the second quarter, and APLS stock surged.
Apellis'' Pegcetacoplan Showed Continuous, Meaningful Effects At Month 18 In Geographic Atrophy Studies
03:41pm, Wednesday, 16'th Mar 2022 Benzinga
Apellis Pharmaceuticals Inc (NASDAQ: APLS ) announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan continued to reduce geographic atrophy (GA) lesion growth . These data will be included in the U.S. marketing application that the Company plans to submit in Q2 of 2022. In the OAKS study, pegcetacoplan reduced GA lesion growth … Full story available on Benzinga.com
